Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

CONTINUE READING »
Technology
Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

CONTINUE READING »
News
  • July, 21 2014  | Aduro receives breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy  READ IT HERE
  • July, 17 2014  | Aduro names industry veteran and academic leader, Gerald Chan, DSc to its board of directors  READ IT HERE
  • June, 11 2014  | Aduro secures $55 million Series C financing  READ IT HERE
  • June, 02 2014  | Aduro announces ASCO presentation of promising results from Phase 1b clinical trial of its novel immunotherapy for the treatment of mesothelioma  READ IT HERE
  • May, 29 2014  | Aduro announces license agreement with Johnson & Johnson Innovation for novel immunotherapies for prostate cancer  READ IT HERE
  • May, 20 2014  | Aduro announces pancreatic cancer and mesothelioma abstracts to be presented at 2014 ASCO annual meeting  READ IT HERE
SEE MORE NEWS »
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use